AU2173899A - Hydroxylation activated prodrugs - Google Patents

Hydroxylation activated prodrugs

Info

Publication number
AU2173899A
AU2173899A AU21738/99A AU2173899A AU2173899A AU 2173899 A AU2173899 A AU 2173899A AU 21738/99 A AU21738/99 A AU 21738/99A AU 2173899 A AU2173899 A AU 2173899A AU 2173899 A AU2173899 A AU 2173899A
Authority
AU
Australia
Prior art keywords
hydroxylation
activated prodrugs
prodrugs
hydroxylation activated
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21738/99A
Other languages
English (en)
Inventor
Michael Danny Burke
Paul Crispin Butler
Lawrence Hylton Patterson
Gerard Andrew Potter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
De Montfort University
Original Assignee
De Montfort University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802522.4A external-priority patent/GB9802522D0/en
Application filed by De Montfort University filed Critical De Montfort University
Publication of AU2173899A publication Critical patent/AU2173899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/36Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00Thiocarboxylic acids
    • C07C327/38Amides of thiocarboxylic acids
    • C07C327/48Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57Nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU21738/99A 1998-02-06 1999-02-02 Hydroxylation activated prodrugs Abandoned AU2173899A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9802522 1998-02-06
GBGB9802522.4A GB9802522D0 (en) 1998-02-06 1998-02-06 Hydroxylation activated prodrugs
US09/115,015 US6214886B1 (en) 1998-02-06 1998-07-14 Hydroxylation activated prodrugs
US09115015 1998-07-14
PCT/GB1999/000155 WO1999040056A1 (en) 1998-02-06 1999-02-02 Hydroxylation activated prodrugs

Publications (1)

Publication Number Publication Date
AU2173899A true AU2173899A (en) 1999-08-23

Family

ID=26313066

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21738/99A Abandoned AU2173899A (en) 1998-02-06 1999-02-02 Hydroxylation activated prodrugs

Country Status (9)

Country Link
US (2) US6677383B1 (https=)
EP (1) EP1051383B1 (https=)
JP (1) JP4642226B2 (https=)
AT (1) ATE272040T1 (https=)
AU (1) AU2173899A (https=)
CA (1) CA2319836C (https=)
DE (1) DE69918950T2 (https=)
ES (1) ES2226332T3 (https=)
WO (1) WO1999040056A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4642226B2 (ja) 1998-02-06 2011-03-02 デ モントフォート ユニヴァーシティ ヒドロキシル化により活性化されたプロドラッグ
GB2334256A (en) 1998-02-12 1999-08-18 Univ Montfort Hydroxylation activated prodrugs
US7321050B2 (en) 1999-12-06 2008-01-22 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
WO2001042231A2 (en) * 1999-12-06 2001-06-14 Welichem Biotech Inc. Polyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors
GB0007401D0 (en) 2000-03-27 2000-05-17 Cancer Res Campaign Tech Substituted chalcones as therapeeutic compounds
GB2378948B (en) * 2000-04-13 2004-11-10 Hsc Res Dev Lp Novel compounds for modulating cell proliferation
ES2299560T3 (es) 2001-02-22 2008-06-01 University Of Bradford Derivados de pirrolindol y de pirroloquinolina como profarmacos para el tratamiento de tumores.
EP1408960B1 (en) 2001-02-22 2006-05-31 School Of Pharmacy, University Of London Benz-indole and benzo-quinoline derivatives as prodrugs for tumour treatment
US6589997B2 (en) * 2001-06-29 2003-07-08 North Shore-Long Island Jewish Health System Small-molecule modulators of hepatocyte growth factor/scatter factor activities
GB0123777D0 (en) * 2001-10-03 2001-11-21 Cancer Res Ventures Ltd Substituted chalcones as therapeutic agents
GB0123780D0 (en) * 2001-10-03 2001-11-21 Cancer Res Ventures Ltd Substituted chalcones as therapeutic agents
EP1438281A4 (en) * 2001-10-26 2006-04-26 Oxigene Inc FUNCTIONALIZED STILBENE DERIVATIVES USEFUL AS IMPROVED VASCULAR TARGETING AGENTS
GB0126889D0 (en) * 2001-11-08 2002-01-02 Paterson Inst For Cancer Res Compounds and their uses
DE60313339T2 (de) * 2002-07-31 2008-01-03 Critical Outcome Technologies, Inc. Protein tyrosin kinase inhibitoren
US7629347B2 (en) * 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
EP1591117A4 (en) * 2003-02-04 2006-04-26 Yakult Honsha Kk BCRP (BREAST CANCER RESISTANCE PROTEIN) INHIBITOR
EP1727822A4 (en) * 2004-03-26 2007-05-09 Hsc Res Dev Lp NEW COMPOUNDS FOR MODULATING CELL PROLIFERATION
NZ562143A (en) 2005-03-30 2010-12-24 Yakult Honsha Kk Dimethoxyphenyl-acrylonitrile derivatives and uses thereof in the treatment of cancer
EP2121681B1 (en) 2007-01-11 2015-04-15 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
US7784455B1 (en) * 2007-09-18 2010-08-31 Chong Carlton Le Loong Reusable pellet shooting grenade
CA2710039C (en) * 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
GB0803071D0 (en) * 2008-02-20 2008-03-26 Care Technologies Inc Cancer detection methods and techniques
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
EP2552915B1 (en) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
AU2019216531A1 (en) 2018-02-02 2020-09-24 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6176433A (ja) * 1984-09-21 1986-04-18 Toyobo Co Ltd 新規なカルコン誘導体
US5773435A (en) 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
AU632992B2 (en) * 1987-12-24 1993-01-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation
US5287386A (en) 1991-03-27 1994-02-15 Thinking Machines Corporation Differential driver/receiver circuit
US5430062A (en) * 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
DE4236237A1 (de) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DE4309344A1 (de) 1993-03-23 1994-09-29 Gerhard Prof Dr Eisenbrand Antineoplastische Mittel mit verstärkter Wirksamkeit
US5276058A (en) * 1993-06-09 1994-01-04 Nippon Hypox Laboratories Incorporated 3,4-dihydroxychalcone derivatives
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
FR2710798B1 (fr) 1993-09-27 1995-11-10 Alcatel Mobile Comm France Chaîne d'amplification en mode de courant, amplificateur opérationnel, cellule de gain et élément d'amplification correspondants.
JPH08188546A (ja) * 1995-01-04 1996-07-23 Kyowa Hakko Kogyo Co Ltd カルコン誘導体
GB9519490D0 (en) 1995-09-25 1995-11-29 Melvin William T Use of a cytochrome P450 enzyme in tumour cells as a marker and target
US5966032A (en) 1996-09-27 1999-10-12 Northern Telecom Limited BiCMOS transceiver (driver and receiver) for gigahertz operation
GB9802522D0 (en) 1998-02-06 1998-04-01 Montford University De Hydroxylation activated prodrugs
JP4642226B2 (ja) 1998-02-06 2011-03-02 デ モントフォート ユニヴァーシティ ヒドロキシル化により活性化されたプロドラッグ
GB2334256A (en) 1998-02-12 1999-08-18 Univ Montfort Hydroxylation activated prodrugs
WO1999040944A2 (en) 1998-02-12 1999-08-19 De Montfort University Hydroxylation activated drug release

Also Published As

Publication number Publication date
CA2319836C (en) 2010-11-23
DE69918950T2 (de) 2005-07-28
ES2226332T3 (es) 2005-03-16
DE69918950D1 (de) 2004-09-02
US6677383B1 (en) 2004-01-13
WO1999040056A1 (en) 1999-08-12
US6346550B2 (en) 2002-02-12
JP4642226B2 (ja) 2011-03-02
CA2319836A1 (en) 1999-08-12
US20010021717A1 (en) 2001-09-13
EP1051383A1 (en) 2000-11-15
ATE272040T1 (de) 2004-08-15
JP2002502836A (ja) 2002-01-29
EP1051383B1 (en) 2004-07-28

Similar Documents

Publication Publication Date Title
AU2173899A (en) Hydroxylation activated prodrugs
MXPA02002901A (es) Enzimas de ruta de enfocado lisosomal.
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
AU4674599A (en) Novel therapeutic agents that modulate enzymatic processes
WO1999057325A3 (en) Enzymes mixture
AU3026399A (en) An enzymatic oil-degumming process
AU5630999A (en) Endofucanases and method using same for preparing fuco-oligosaccharides from fucanes, bacterium producing endofucanases and uses of fuco-oligosaccharides for plant protection
AU3749199A (en) Carotenoid biosynthesis enzymes
AU2531599A (en) Hydroxylation activated drug release
AU5597098A (en) Inhibitors of the enzymatic activity of psa
WO1995013095A3 (en) Therapy
AU3874900A (en) Enzymatic reductions with dihydrogen via metal catalyzed cofactor regeneration
HK1039449A1 (zh) 治疗多发性硬化的方法
WO1996035415A3 (en) Use of sesquiterpenes for inhibiting oxidative enzymes
AU2003233222A1 (en) Aqueous polyurethane preparations
AU6839300A (en) Nucleic acids which code for the enzyme activities of the spinosyn biosynthesis
AU2002220697A1 (en) Isolated luciferases lu164, lual and lu22, and the use of the same
AU8334798A (en) A composition comprising an enzyme having galactose oxidase activity and use thereof
AU1719497A (en) An enzyme with pectin esterase activity
AU6216699A (en) Cytochrome p450 electrochemical system
AU2356001A (en) Surface treatment agent for laminated fabric
AU4693199A (en) Reduced carbon from under-oxidized burner
WO2001007087A8 (en) Enzyme catalyzed anti-infective therapeutic agents
AU1261601A (en) Treatment of C. difficile toxin B associated conditions
AU2003268634A1 (en) Culture having phenol oxidase-like activity

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase